Avanir Pharmaceuticals Inc - Company & Market Research Reports

Avanir Pharmaceuticals focuses on the research, development and commercialization of novel medical and pharmaceutical treatments for people with central nervous system disorders. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. Avanir Pharmaceuticals was founded in 1988 and is headquartered in Aliso Viejo, California.

Global Lifestyle Drugs Market 2017-2021 - Product Thumbnail Image

Global Lifestyle Drugs Market 2017-2021

  • Report
  • 91 Pages
From
Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • 204 Pages
From
Alzheimer's Disease - Pipeline Review, H2 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2018

  • Report
  • 1333 Pages
From
Alzheimer's Disease: Competitive Landscape to 2026 - Product Thumbnail Image

Alzheimer's Disease: Competitive Landscape to 2026

  • Report
  • 49 Pages
From
Pain Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Pain Drug Development Pipeline Review, 2017

  • Report
  • 229 Pages
From
Schizophrenia - Pipeline Review, H1 2018 - Product Thumbnail Image

Schizophrenia - Pipeline Review, H1 2018

  • Report
  • 334 Pages
From
Global Neuropathy Pain Treatment Market 2017-2021 - Product Thumbnail Image

Global Neuropathy Pain Treatment Market 2017-2021

  • Report
  • 70 Pages
From
Global Central Nervous System Disorders Therapeutics Market 2016-2020 - Product Thumbnail Image

Global Central Nervous System Disorders Therapeutics Market 2016-2020

  • Report
  • 147 Pages
From
Onzetra Xsail 2016 U.S Promotional Report - Product Thumbnail Image

Onzetra Xsail 2016 U.S Promotional Report

  • Report
  • 21 Pages
From
Nuedexta 2016 U.S Promotional Report - Product Thumbnail Image

Nuedexta 2016 U.S Promotional Report

  • Report
  • 21 Pages
From
Intranasal Drug Delivery - Global Strategic Business Report - Product Thumbnail Image

Intranasal Drug Delivery - Global Strategic Business Report

  • Report
  • 239 Pages
From
Depression - Pipeline Review, H1 2018 - Product Thumbnail Image

Depression - Pipeline Review, H1 2018

  • Report
  • 490 Pages
From
Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027 - Product Thumbnail Image

Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027

  • Drug Pipelines
  • 169 Pages
From
Major Depressive Disorder - Pipeline Review, H2 2016 - Product Thumbnail Image

Major Depressive Disorder - Pipeline Review, H2 2016

  • Report
  • 201 Pages
From
Treatment Resistant Depression - Pipeline Review, H2 2016 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Review, H2 2016

  • Report
  • 74 Pages
From
Serotonin Transporter Inhibitor -Pipeline Insight, 2018 - Product Thumbnail Image

Serotonin Transporter Inhibitor -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Sigma Receptor Agonist -Pipeline Insight, 2018 - Product Thumbnail Image

Sigma Receptor Agonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Treatment Resistant Depression - Pipeline Insight, 2018 - Product Thumbnail Image

Treatment Resistant Depression - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Traumatic Brain Injury - Pipeline Review, H2 2018 - Product Thumbnail Image

Traumatic Brain Injury - Pipeline Review, H2 2018

  • Report
  • 306 Pages
From
Migraine - Pipeline Review, H1 2018 - Product Thumbnail Image

Migraine - Pipeline Review, H1 2018

  • Report
  • 220 Pages
From
Loading Indicator
adroll